09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)
02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share
25/05/2026 – Following release of 2025 results and securing of clinical trial insurance policy, Maxim Group reiterates its buy recommendation on AB Science’s stock with a target price of EUR 4.0 per share
13/05/2026 – AB Science reports its revenues for the year 2025 and provides an update on its activities
29/04/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors
27/04/2026 – AB Science announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt and the 12-month deferral of repayment of a loan subscribed with the EIB
20/04/2026 – AB Science announced the publication of a new article on the preprint platform medRxiv, evaluating long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study
16/04/2026 – AB Science provides an update on its clinical development program
24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS)
09/02/2026 – AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors